Manual práctico de Trombosis y Hemostasia de la SETH

I I I . H E M O ST A S I A E N L A P R Á C T I C A C L Í N I C A — 2 4 2 — 43. American Society of Hematology. Clinical Practice Guideline on the Evaluation and Management of vonWillebrand Disease; 2012. 44. Kadir RA, James AH. Reproductive health in women with blee- ding disorders.World Federation of Hemophilia (WFH), 2009. 45. American College of Obstetricians and Gynecologists. Committee opinion.VonWillebrand disease in women. Number 451, 2015. 46. Kuhl H, Birkhäuser M, Mueck A, Neulen J, Thaler C, Kiesel L, Braendle W. Long-cycle treatment in oral contraception. Ther Umsch 2009;66:101-8. 47. Royal College of Obstetricians and Gynaecologists. Green-top guideline No. 40. Venous Thromboembolism and Hormonal Contraception; 2010. 48. Martínez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 2007;12:97-106. 49. Kemmeren IM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1-7. 50. Martínez F, Ramírez I, Pérez-Campos E, Latorre K, Lete I.Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Con- tracept Reprod Health Care 2012;17:7-29. 51. FDA Office of Surveillance and Epidemiology. Combined Hor- monal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. CHC-CVD final report 111022v2. FDA ; 2011. Available from: http://www.fda.gov/downloads/Drugs/Drug Safety/UCM277384.pdf 52. Lidegaard O, Lokkegaard E, Svendsen A,Agger C. Hormonal con- traception and the risk of venous thromboembolism: a national follow up study. BMJ 2009;339:b2890. 53. Van Hylckama V, Helmerhorst F, Vandenbroucke J, Doggen C, Rosendaal F. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921. 54. Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta- analysis. Obstet Gynecol 2013;122(2 Pt 1):380-9. 55. Vinogradova Y, Coupland C, Hippisley J. Use of combined oral contracep-tives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015;350:h2135. 56. De Bastos M, Stegeman BH, Rosendaal FR, van HylckamaVlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contracepti- ves: venous thrombosis (Review).The Cochrane Collaboration; 2014. 57. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral con- traceptives and venous thromboembolism. A Systematic Review and Meta-Analysis. Drug Saf 2012;35:191-205. 58. Conferencia de Consenso de la SEC 2011. Actualización en el manejo clínico de la AH, Intrauterina y de Urgencia. Madrid: Gru- po editorial Entheos; 2012. 59. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories of American Heart Association. Circulation 1998;97:1837-47. 60. Practice Committee of American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thrombo-embolism: a guideline. Fertil Steril 2017; 107:43-51. 61. Canonico M, Plu-Bureau G, Lowe G, Scarabin PY. Hormone re- placement therapy and risk of venous thromboembolism in post- menopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31. 62. Renoux C, Dell’Aniello S, Suissa S. Hormone replacement thera- py and the risk of venous thromboembolism: a population based study. J Thromb Haemost 2010;8:979-86. 63. Tremollieres F, Brincat M, Erel CT, Gambacciabi M, Lambrinoudaki I, Moen MH, et al. EMAS position statement: managing menopau- sal women with a personal or family history of VTE. Maturitas 2011;69:190-3. 64. Royal College of Obstetricians and Gynaecologists. Green-top guideline No. 19. Venous thrombo-embolism and hormone replacement therapy; 2011. 65. American College of Obstetricians and Gynaecologists. Commi- ttee Opinion No. 556. Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 2013;121:887-90. 66. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A me- ta-analysis.Thromb Haemost 2008;99:338-42. 67. Trifiletti A, Gaudio A, Lasco A, Atteritano M, Scamardi R, Pizzoleo MA, et al. Haemostatic effects of phytoestrogen genis- tein in postmenopausal women.Thromb Res 2008;123:231-5.